Derrell Porter

[Derrell Porter @derrellp]

I am honored and excited to join the Board of Acumen, an innovative exciting biotech focused on #alzheimersdisease with ACU193. They are pioneering in the field of amyloid-beta oligomers and the development of therapeutics for this devastating condition.…https://t.co/vHEKAW6LMm

[Derrell Porter @derrellp]

Treatment with virus specific T-cells has shown promising clinical results…more on that, including details on CE-VST01-JC coming next week!

PML review paper here https://t.co/Rwv7jMSUfj
6/6

[Derrell Porter @derrellp]

We’ve been sharing a lot about Cellevolve’s lead program, CEVST01-JC, which is focused on PML. You maybe asking "what exactly is PML"? Here is a 6 part thread on this disease🧵

[Derrell Porter @derrellp]

PML is diagnosed through a combo of clinical, radiological, and laboratory findings. Diagnosis is often delayed due to lack of awareness. There are no approved therapies, and clinical management is focused on stopping immunosuppressive treatment, or starting HAART for HIV. 5/6

[Derrell Porter @derrellp]

Brain cancer continues to be one of the most challenging diseases and no effective therapies exist. Especially for children, as it is the top cause of cancer death in kids. Diffuse intrinsic pontine glioma (DIPG), is a specific typ…https://t.co/1IyOgLwryP https://t.co/sxhJDl99aW

[Derrell Porter @derrellp]

Earlier this year, we announced a global collaboration with Seattle Children's Therapeutics and The Cure Factory on the BrainChild research program. This has the potential to transform the lives of children with CNS tumors, the #1…https://t.co/XwyfO515Po https://t.co/8211OQ2YY9

[Derrell Porter @derrellp]

Critical step on our journey to transform innovations into treatments. Excited and proud of Cellevolve reaching this huge milestone!!! https://t.co/KzPKffv0MS

[Derrell Porter @derrellp]

What an inspirational story!! For someone to accomplish so much in his brief time on earth is phenomenal. For someone who loves neuroscience, excellence, football, and giving back, all the more impressive! #neuroscience #physicians https://t.co/q2gpfNOmeN

[Derrell Porter @derrellp]

Congratulations Drs. Rezvani and Ethan Li!! Love what you are doing in CAR NK's👏👏

[Katy Rezvani, M.D., Ph.D @lab_rezvani]

Incredibly proud of Ye Ethan Li for having his PhD project published in Nat Med. His paper shows that trogocytosis drives relapse post CAR NK therapy & that modulating NK signaling can improve CAR NK efficacy. Congratulations Ethan! @KenChen @UH_NVLab
https://t.co/Wtpc3dWtPG

[Derrell Porter @derrellp]

Cellevolve Bio Submits Investigational New Drug (IND) Application for Global Phase 2, Placebo-controlled Study of ... https://t.co/qBHU2di6yQ

[Derrell Porter @derrellp]

Cellevolve Bio Submits Investigational New Drug (IND) Application for Global Phase 2, Placebo-controlled Study of ... https://t.co/qBHU2di6yQ

[FOX College Hoops @CBBonFOX]

RT if your school has a 2022 NBA Champion 🏆

[Derrell Porter @derrellp]

Congratulations Krishna. Well deserved and can’t wait to connect here in SF!! @cellevolve

[Krishna Komanduri, MD, FASTCT @drkomanduri]

Lots of bittersweet emotions now but for the moment I want to extend my thanks to @Bob_Wachter and @UCSFCancer @UCSFHospitals leadership for this profound privilege.

But also profound gratitude to my incredible family at @SylvesterCancer during my time here.

More to come. 🙏🏽

[Derrell Porter @derrellp]

Kudos Luke. Very impressive 🙏🏽

[David Sable @dbsable]

Not every biotech entrepreneurship success involves drug development. Kudos to Luke on building one of the great publications and brands in healthcare journalism. @ldtimmerman @timmermanreport

[Derrell Porter @derrellp]

@rtnarch Congratulations @rtnarch !! Very impressive roster of scientific minds. Looking forward to seeing the impact on the field

[Derrell Porter @derrellp]

Love all of them esp #ErinHarris and @ldtimmerman

[Derrell Porter @derrellp]

Congratulations to @CincyChildrens on needed infrastructure

[Patrick J. Hanley 🧬 @DrPHanley]

Wow - @CincyChildrens to team with @CTIClinical to provide $100M to build cell & gene therapy manufacturing infrastructure. I hope this leads to better patient access and new treatments for rare diseases. H/T @Eskandanian #celltherapy #genetherapy
https://t.co/wNGdorxgqz